NEW YORK CITY (dpa-AFX) - Drug major Pfizer, Inc. (PFE) announced Thursday
that the company has selected its preferred once-daily modified release
formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor
agonist, based on results from the ongoing pharmacokinetic study (NCT06153758).

Pfizer plans to conduct dose optimization studies in the second half of 2024
evaluating multiple doses of the preferred modified release formulation to
inform the registration enabling studies.

The ongoing open-label, randomized study is evaluating the pharmacokinetics and
safety of immediate- and modified release formulations of danuglipron
administered orally in healthy adults 18 years or older.

To date, study results have demonstrated a pharmacokinetic profile supportive of
once-daily dosing, with a safety profile consistent with prior danuglipron
studies including no liver enzyme elevations observed in more than 1,400 study
participants.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX